COVID–19 Data Transparency Act

I 116TH CONGRESS 2D SESSION H. R. 7674 To require the Director of the Centers for Disease Control and Prevention to create a standardized method for State, Tribal, and local health departments to report to the Centers with respect to COVID–19, and for other purposes. IN THE HOUSE OF REPRESENTATIVES JULY 20, 2020 Mr. BEYER (for himself, Ms. SEWELL of Alabama, Mr. GARCI´A of Illinois, Mr. SERRANO, Ms. SCANLON, Mr. HORSFORD, Mr. CONNOLLY, Mr. PERL- MUTTER, Mr. LIPINSKI, Mr. CISNEROS, Ms. DEAN, Mr. PASCRELL, Mr. SUOZZI, Mr. LANGEVIN, Ms. MCCOLLUM, Mrs. AXNE, Ms. PORTER, Mr. GARAMENDI, Mr. GRIJALVA, Mrs. WATSON COLEMAN, Ms. GABBARD, Mr. CA´RDENAS, Mr. WELCH, Mrs. LAWRENCE, Mr. SABLAN, Ms. SHERRILL, Ms. SPANBERGER, Mr. GONZALEZ of Texas, and Mr. ENGEL) introduced the following bill; which was referred to the Committee on En- ergy and Commerce A BILL To require the Director of the Centers for Disease Control and Prevention to create a standardized method for State, Tribal, and local health departments to report to the Centers with respect to COVID–19, and for other purposes. Be it enacted by the Senate and House of Representa- 1 tives of the United States of America in Congress assembled, 2 VerDate Sep 11 2014 21:33 Aug 09, 2020 Jkt 099200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H7674.IH H7674 kjohnson on DSK79L0C42PROD with BILLS 2 •HR 7674 IH SECTION 1. SHORT TITLE. 1 This Act may be cited as the ‘‘COVID–19 Data 2 Transparency Act’’. 3 SEC. 2. STANDARDIZED METHOD FOR HEALTH DEPART- 4 MENT REPORTING. 5 (a) IN GENERAL.—Not later than 30 days after the 6 date of enactment of this Act, the Director of the Centers 7 for Disease Control and Prevention shall create a stand- 8 ardized method for State, Tribal, and local health depart- 9 ments to report to the Centers with respect to COVID– 10 19 the following: 11 (1) Daily hospitalizations of patients in the re- 12 spective jurisdiction with a confirmed or presumed 13 case of COVID–19. 14 (2) Daily numbers of such patients in the inten- 15 sive care unit. 16 (3) Daily numbers of such patients on ventila- 17 tors. 18 (4) How long such patients have been in the 19 hospital. 20 (5) Daily numbers of diagnostic and serological 21 tests administered for SARS–CoV–2 with respect to 22 patients in the respective jurisdiction, disaggregated 23 by— 24 (A) the type of test; and 25 VerDate Sep 11 2014 21:33 Aug 09, 2020 Jkt 099200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H7674.IH H7674 kjohnson on DSK79L0C42PROD with BILLS 3 •HR 7674 IH (B) the testing positivity rate of each type 1 of test. 2 (6) The sensitivity and specificity of each such 3 type of test. 4 (7) Daily numbers and percentages of contacts 5 traced with respect to patients in the respective ju- 6 risdiction. 7 (8) The rate of transmission of SARS–CoV–2 8 in the respective jurisdiction. 9 (b) POSTING BY CDC.—The Director of the Centers 10 for Disease Control and Prevention shall— 11 (1) post the information described in para- 12 graphs (1) through (8) of subsection (a), to the ex- 13 tent such information is in the possession of the 14 Centers, on the public website of the Centers, except 15 that such posting shall exclude any individually iden- 16 tifiable information; and 17 (2) to the extent feasible disaggregate such in- 18 formation by State, Tribal, and local jurisdiction. 19 (c) UPDATES.—The Director of the Centers for Dis- 20 ease Control and Prevention— 21 (1) shall, as appropriate, periodically update the 22 method posted under subsection (a); and 23 VerDate Sep 11 2014 21:33 Aug 09, 2020 Jkt 099200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H7674.IH H7674 kjohnson on DSK79L0C42PROD with BILLS 4 •HR 7674 IH (2) may revise and expand the reporting cat- 1 egories listed in such subsection. 2 Æ VerDate Sep 11 2014 21:33 Aug 09, 2020 Jkt 099200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6301 E:\BILLS\H7674.IH H7674 kjohnson on DSK79L0C42PROD with BILLS